Cannabidiol Alleviates Neurological Deficits After Traumatic Brain Injury by Improving Intracranial Lymphatic Drainage
The study by Shiying Dong and colleagues (Journal of Neurotrauma, 2024) investigated the therapeutic effects of cannabidiol (CBD) in a murine model of traumatic brain injury (TBI), focusing on its impact on intracranial lymphatic drainage and glymphatic function. In the experiments, mice received oral CBD (pretreatment and/or post-injury administration) following TBI induction. Researchers assessed neurological outcomes through behavioral tests for motor, sensory, memory, and cognitive function; measured meningeal lymphatic vessel (MLV) drainage and tracer clearance to deep cervical lymph nodes (dCLNs); evaluated glymphatic system efficiency; monitored cerebral blood flow; and quantified toxic metabolites (such as phosphorylated tau, amyloid-β, and glutamate via cortical microdialysis).
Key findings showed that CBD significantly improved MLV drainage and glymphatic clearance of intracranial tracers, accelerated metabolite elimination, increased cerebral blood flow, and reduced accumulation of neurotoxic proteins and excitotoxic glutamate. This mechanism led to notable amelioration of neurological deficits: treated mice exhibited better motor and sensorimotor recovery, enhanced cognitive and memory performance, and overall improved functional outcomes compared to untreated TBI controls. The authors conclude that CBD alleviates post-TBI neurological impairments primarily by bolstering the brain’s lymphatic drainage pathways (MLVs and dCLNs), which helps clear toxic metabolites and supports recovery, positioning early CBD administration as a promising strategy for TBI therapy, though human translation would require further validation. Overall, this preclinical work provides mechanistic insight into CBD’s neuroprotective potential beyond anti-inflammatory or antioxidant effects, highlighting lymphatic system modulation as a novel target in brain injury.
Read More: